
    
      Sphincteric incompetence is most commonly found in men who have had radical prostatectomy
      (RP). RP is the most common treatment for localized high-risk Prostate Cancer in North
      America.

      The ContinoÂ®, a urethral insert, was conceived by a prostate cancer survivor and worn for 10+
      years without incident, and a First in Human clinical trial was completed without serious
      adverse event. The basis for this clinical trial is a post market clinical follow-up study.
      No drug treatment will be administered.
    
  